Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Elsulfavirine in Healthy Volunteers
NCT05148754Phase 1Completed
- Sponsor
- Viriom Inc
- Start
- Jan 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of elsufavirine in coronavirus disease 2019 (COVID-19) and human immunodeficiency virus type 1 infection (HIV-1) (4 arms), sponsored by Viriom Inc. Primary endpoints: Pharmacokinetics of Elsulfavirine at 39 days and Incidence of Adverse Events and Serious Adverse Events at 39 days. Started Jan 2021; status: completed.
02
Drugs
elsufavirine
03
Conditions
coronavirus disease 2019 (COVID-19)human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05148754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05148754.